Shearman & Sterling represented HeartWare International, Inc. in connection with a concurrent public offering of $143.75 million principal amount of 3.50% convertible senior notes due 2017 and a secondary offering of 1,000,000 shares of common stock held by Apple Tree Partners I, L.P., one of HeartWare’s existing stockholders, at a price per share of $81.31. HeartWare is a medical device company focused on developing the world's smallest implantable blood pumps for the treatment of advanced heart failure. HeartWare’s shares are listed on the Nasdaq Global Market and the Australian Stock Exchange.

J.P. Morgan Securities LLC acted as the sole book-running manager for both the convertible notes and common stock offerings. Canaccord Genuity Inc., Lazard Capital Markets LLC and Wells Fargo Securities, LLC acted as co-managers of the offerings. HeartWare intends to use the net proceeds from the notes offering for general corporate and working capital purposes, including, but not limited to, research and development, expansion of its manufacturing capabilities and/or licensing of or investment in complementary products, technologies or businesses.

The following Shearman & Sterling lawyers advised HeartWare in the transaction: partners Danielle Carbone (New York-Capital Markets), Robert Evans (New York-Capital Markets), Don Lonzcak (Washington, DC-Tax), Samuel Waxman (New York-Intellectual Property Transactions), and Paul Schreiber (New York-Investment Funds) and associates Irene Shih (New York-Capital Markets), Sheila Lavu (New York-Capital Markets), Gabriela Laufer (New York-Capital Markets), Dorothea Athanasiadou ( New York-Capital Markets), Jennifer Val (New York-Capital Markets), Gerald Feige (Washington, DC-Tax), Timothy Franklin (New York-Intellectual Property Transactions), Jesse Kanach (Washington, DC-Investment Funds) and Steve Homan (New York-Investment Funds).